Kymera Therapeutics, Inc.

US$131.73As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:KYMRHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR 25.76%
Div yield —
ROE (27.29%)
Biotechnology
Beta (5Y) 2.03
PE TTM —
TSR TTM 113.02%
Mkt cap US$11.25B
ROIC (18.60%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$148
12.48%
(95.82%)
Hold 8|7|12|1|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.90
2.03
2.17
2.42
6.79%
6.78%
12.73%
30.64%
Revenue$M
850.7
852.0
897.9
944.5
11.55%
11.12%
10.50%
14.83%
Peers (US$11.25B)
Cap (US$)
PE
11.43B
66.21x
Capital
TTM
5Y
10Y
Leveragex
7.339
0.498
0.557
EBIT/Intx
0.104
1.160
1.122
Own earn%
68.81
(44.74)
(52.95)
Sh yield%
39.50
56.26
56.88
Owners
Insiders/Inst%
2.03
31.72
Short interest%
3.99
SBC / revenue%
3.46
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
5–8
$1 testx
—
Incr. ROIC%
−1